• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Obagi Medical Announces the Launch of Latest Innovations in The SUZANOBAGIMD® Collection

    2/10/25 9:00:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $WALD alert in real time by email

    2.Social Reveal _1_1080x1920

    NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), a leader in advanced skincare innovation and the originator of medical-grade skincare, proudly unveils the latest groundbreaking additions to its highly regarded SUZANOBAGIMD® collection. The new products - Super Antioxidant Serum and Moisture Restore Hydration Replenishing Cream - offer cutting-edge solutions to address common skincare concerns such as skin discoloration and brightening, oxidative stress, and skin hydration to maintain a healthy skin barrier function. Formulated to be safe and effective for all skin types—whether sensitive, oily, dry, or somewhere in between—Obagi's inclusive approach ensures that everyone can experience the benefits of advanced skincare, no matter their unique needs or concerns.

    Developed by Dr. Suzan Obagi, a distinguished dermatologist and the Chief Medical Director at Obagi, the powerhouse duo of skincare solutions reflects her extensive research and expertise in dermatologic surgery and skin health. Her expertise in formulation is drawn from her extensive experience treating thousands of patients each year, addressing a wide range of concerns. The most common issues she observes are hyperpigmentation and challenges with sensitive skin. Dr. Obagi's groundbreaking work, especially in understanding the unique needs of skin of color and the needs of sensitive skin types, led her to identify the five key pathways essential for optimal skin health. These pathways include reducing pigment formation and visibly improving hyperpigmentation, calming redness and reducing skin irritation, combating oxidative stress, supporting cell turnover, and restoring the skin barrier. Dr. Obagi has created effective products that do not irritate the skin while delivering results you can see in as little as a few weeks in some cases.

    Dr. Suzan Obagi, Chief Medical Director at Obagi, commented, "I am so excited to finally share these groundbreaking innovations with the world. These products are the culmination of years of research and patient testing, driven by my passion for helping patients unveil their naturally radiant skin without irritation. By incorporating cutting-edge ingredients like encapsulated silymarin to protect against oxidative stress and multi-weight hyaluronic acids for multi-layered hydration, we've developed solutions that truly push the envelope in skincare. I genuinely believe these novel formulations not only set a new standard but also reflect my unwavering commitment to treating skin holistically, ensuring health, resilience, and a luminous glow for every skin type."

    Drawing on this wealth of expertise in treating skin discoloration, Dr. Obagi formulated these latest additions to her namesake collection to transform skin health and deliver a radiant, brighter complexion. The collection includes the new Super Antioxidant Serum, providing medical-grade defense against oxidative stress for more resilient, radiant and youthful-looking skin. Super Antioxidant Serum is formulated with a potent blend of antioxidants, including encapsulated Silymarin and stabilized Vitamin C, to neutralize free radicals, combat oxidative stress, and brighten skin.

    Moisture Restore Hydration Replenishing Cream is a medical-grade, multi-layered moisturizer which delivers intense, multi-layered hydration. With a blend of both low and high-molecular-weight Hyaluronic Acids this cream delivers moisture to different layers of the skin.

    Delivering both immediate and long-lasting results, these products were clinically tested by Dr. Obagi and third party clinical graders. During testing of Super Antioxidant Serum and Moisture Restore Hydration Replenishing Cream, 94% of subjects felt their skin was refreshed and smoother immediately after a single application* and 97% of subjects observed an improvement in overall skin appearance after 2 weeks* including:

    • Visible improvement in the appearance of fine lines
    • Visible improvement in the appearance of hyperpigmentation
    • Visibly calms irritation and boosts hydration

    Justin Giouzepis, Chief Marketing Officer of Obagi, added, "We're thrilled to partner with Dr. Suzan Obagi on bringing to market Super Antioxidant Serum and Moisture Restore, products designed to address the critical needs of both skin brightening and hydration. Obagi is the leader in innovating products that defend against environmental aggressors with our vitamin C collection and products that treat hyperpigmentation with the Obagi Nu-Derm® collection. Having Super Antioxidant Serum in the Obagi portfolio provides professionals with an additional oxidative stress fighting product to recommend to their patients who may have sensitive skin but don't want to compromise on results. We know achieving radiant, healthy skin shouldn't come at the cost of irritation, which is why we've prioritized gentle yet effective formulations suitable for even the most sensitive skin types. These launches represent our commitment to providing inclusive skincare solutions for everyone."

    The SUZANOBAGIMD® Super Antioxidant Serum, priced at $158, and the SUZANOBAGIMD® Moisture Restore Hydration Replenishing Cream, priced at $78, are now available through partnering professional channels. They will be available for customers to purchase on Obagi.com on 2.24.2025.

    *Results are based on a 2024 2-week clinical test, with subjects using SOMD Super Antioxidant Serum & Moisture Restore Replenishing Cream (if needed) daily within protocol.

    About Obagi Medical

    Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, refined with a legacy of 35 years' experience. First known as leaders in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi products are designed to diminish the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. Backed by science and trusted by professionals, Obagi empowers individuals to achieve healthy, beautiful skin.

    More information about Obagi is available on the brand's website, https://www.obagi.com.

    About Waldencast

    Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand's distinct DNA. The first step in realizing its vision was the business combination with Obagi Cosmeceuticals and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset-light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com/.

    Media Contact:

    [email protected]

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2e3ff584-7c90-4039-9b0e-ab93ef0fcf5a



    Primary Logo

    Get the next $WALD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WALD

    DatePrice TargetRatingAnalyst
    1/14/2026$2.00Buy
    Jefferies
    11/25/2025$3.00Outperform → Market Perform
    Telsey Advisory Group
    4/22/2025$5.00Buy
    Alliance Global Partners
    12/16/2024$4.30Hold
    TD Cowen
    10/25/2024$5.00Buy
    Canaccord Genuity
    5/1/2024$10.00 → $8.00Outperform
    Telsey Advisory Group
    7/24/2023Outperform → Mkt Perform
    Raymond James
    9/9/2022$12.00Buy
    DA Davidson
    More analyst ratings

    $WALD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin's Age and Restore Visible Youthfulness

    NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), is proud to announce the latest innovation in advanced skin science and longevity with the launch of its newest breakthrough: Obagi NU-GEN™ Cellular Renewal Serum. A cellular renewal serum that acts like a power supply for your skin and supports its natural cellular functions. The formula is clinically proven to visibly rewind skin's age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously. At the cor

    3/24/26 8:35:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™

    NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi® saypha® MagIQ™ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluat

    3/19/26 8:29:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast Reports Q4 2025 and FY 2025 Financial Results

    FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o

    3/13/26 6:50:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Waldencast plc with a new price target

    Jefferies resumed coverage of Waldencast plc with a rating of Buy and set a new price target of $2.00

    1/14/26 8:45:39 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast plc downgraded by Telsey Advisory Group with a new price target

    Telsey Advisory Group downgraded Waldencast plc from Outperform to Market Perform and set a new price target of $3.00

    11/25/25 8:37:06 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Alliance Global Partners initiated coverage on Waldencast plc with a new price target

    Alliance Global Partners initiated coverage of Waldencast plc with a rating of Buy and set a new price target of $5.00

    4/22/25 9:24:54 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Brousset Michel

    3 - Waldencast plc (0001840199) (Issuer)

    3/18/26 12:12:49 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 3 filed by new insider Souza Cristiano

    3 - Waldencast plc (0001840199) (Issuer)

    3/18/26 11:25:15 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 3 filed by new insider Thompson Motta Roberto Moses

    3 - Waldencast plc (0001840199) (Issuer)

    3/18/26 11:24:08 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    SEC Filings

    View All

    SEC Form 6-K filed by Waldencast plc

    6-K - Waldencast plc (0001840199) (Filer)

    3/13/26 6:47:02 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 20-F filed by Waldencast plc

    20-F - Waldencast plc (0001840199) (Filer)

    3/13/26 6:46:32 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 6-K filed by Waldencast plc

    6-K - Waldencast plc (0001840199) (Filer)

    3/11/26 4:16:12 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Financials

    Live finance-specific insights

    View All

    Waldencast Reports Q4 2025 and FY 2025 Financial Results

    FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o

    3/13/26 6:50:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date

    LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review. About Waldencast plc Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned

    3/11/26 4:05:00 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update

    Transformation efforts drive performance improvements at Obagi Medical with accelerating revenue Contrasted performance for Milk Makeup with Q2 2025 net revenue growth driven by U.S. channel expansion and sell-out acceleration but softer performance in Q3 2025 in international markets Company advances key strategic initiatives, including expansion into medical aesthetics through the Novaestiq acquisition and strengthened balance sheet following the sale of the Obagi Japan trademark and credit facility refinancing Waldencast updates FY 2025 guidance to reflect current trends and purposeful investments to drive long-term growth LONDON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NA

    11/24/25 6:45:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Leadership Updates

    Live Leadership Updates

    View All

    Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™

    NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi® saypha® MagIQ™ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluat

    3/19/26 8:29:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Shareholders Elect Four Independent Directors to the Six Flags Board

    Six Flags Entertainment Corporation (NYSE:FUN), the largest regional amusement park operator in North America, announced today that its shareholders elected Sandra (Sandy) Cochran, Michael Colglazier, Felipe Dutra, and Steven Hoffman to the Board of Directors of Six Flags Entertainment Corporation for 3-year terms expiring in 2028. Shareholders also confirmed the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm, approved an advisory vote on the compensation of the Company's named executive officers, and confirmed a 1-year frequency for shareholder advisory votes on executive compensation. "I want to welcome Sandy, Michael, Felipe and St

    6/25/25 5:00:00 PM ET
    $BUD
    $CBRL
    $DG
    Beverages (Production/Distribution)
    Consumer Staples
    Restaurants
    Consumer Discretionary

    Milk Makeup to Launch at Ulta Beauty This Spring

    The New York City based award-winning clean color cosmetics brand will expand to select Ulta Beauty stores nationwide and online, marking a significant milestone since its debut in 2016 NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Milk Makeup, the trailblazing clean beauty brand celebrated for its iconic, high-performance formulas, inclusive ethos and part of the Waldencast plc (NASDAQ:WALD) platform, is thrilled to announce an expansion into the nation's largest beauty retailer, Ulta Beauty. Beginning this spring, Milk Makeup's cult-favorite products, including the 13x award-winning Hydro Grip Primer and internet-breaking Cooling Water Jelly Tints will be available in 600+ Ulta Beauty stores nat

    1/28/25 6:45:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Waldencast plc (Amendment)

    SC 13D/A - Waldencast plc (0001840199) (Subject)

    2/9/24 6:25:08 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13G filed by Waldencast plc

    SC 13G - Waldencast plc (0001840199) (Subject)

    2/1/24 5:17:40 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13G/A filed by Waldencast plc (Amendment)

    SC 13G/A - Waldencast plc (0001840199) (Subject)

    1/31/24 10:23:25 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary